This article is from the source 'guardian' and was first published or seen on . The next check for changes will be

You can find the current article at its original source at https://www.theguardian.com/us-news/2025/may/21/moderna-withdraws-application-combined-flu-covid-vaccine

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Moderna withdraws application for US approval of combined flu-Covid shot Moderna withdraws application for US approval of combined flu-Covid shot
(about 2 hours later)
After talks with Food and Drug Administration, company plans to resubmit vaccine application later this yearAfter talks with Food and Drug Administration, company plans to resubmit vaccine application later this year
Moderna said on Wednesday it had withdrawn an application seeking approval for its flu and Covid combination vaccine candidate after discussions with the US Food and Drug Administration.Moderna said on Wednesday it had withdrawn an application seeking approval for its flu and Covid combination vaccine candidate after discussions with the US Food and Drug Administration.
The company said it would resubmit the application later this year with vaccine efficacy data from a late-stage trial of its experimental seasonal influenza vaccine, which it expects to report this summer.The company said it would resubmit the application later this year with vaccine efficacy data from a late-stage trial of its experimental seasonal influenza vaccine, which it expects to report this summer.
The decision comes a day after the US FDA said it would require new clinical trials for approval of annual Covid-19 boosters for healthy people under 65 years. The decision comes a day after the US FDA said it would require new clinical trials for approval of annual Covid-19 boosters for healthy people under 65 years old.
Shares of the company have been battered by declining Covid revenue as well as investor concerns spurred by the appointment of the vaccine skeptic Robert F Kennedy Jr as secretary of the Department of Health and Human Services.Shares of the company have been battered by declining Covid revenue as well as investor concerns spurred by the appointment of the vaccine skeptic Robert F Kennedy Jr as secretary of the Department of Health and Human Services.
The shares fell another 1.4% in premarket trading on Wednesday.The shares fell another 1.4% in premarket trading on Wednesday.
The FDA is due to make a decision on Moderna’s next-generation Covid-19 vaccine, which is a component of the combination flu-Covid shot, by the end of the month. Moderna has previously said it does not expect a delay in that decision.The FDA is due to make a decision on Moderna’s next-generation Covid-19 vaccine, which is a component of the combination flu-Covid shot, by the end of the month. Moderna has previously said it does not expect a delay in that decision.
Moderna in early May pushed back the time frame for likely approval of its combination vaccine – meant to protect adults aged 50 and above against both Covid-19 and influenza – to 2026.Moderna in early May pushed back the time frame for likely approval of its combination vaccine – meant to protect adults aged 50 and above against both Covid-19 and influenza – to 2026.
The company has been banking on revenue from newer mRNA shots to make up for falling sales of its Covid vaccine and less-than-expected uptake of its respiratory syncytial virus vaccine, which sent its shares down nearly 60% last year.The company has been banking on revenue from newer mRNA shots to make up for falling sales of its Covid vaccine and less-than-expected uptake of its respiratory syncytial virus vaccine, which sent its shares down nearly 60% last year.